Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,097 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer.
Takahashi M, Watanabe S, Suzuki R, Arita M, Sato K, Sato M, Sekiya Y, Abe Y, Fujisaki T, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Saida Y, Hokari S, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Takahashi M, et al. Among authors: hayashi m. Cancer Immunol Immunother. 2022 Jun;71(6):1357-1369. doi: 10.1007/s00262-021-03078-0. Epub 2021 Oct 17. Cancer Immunol Immunother. 2022. PMID: 34657194 Free PMC article.
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
Watanabe S, Ota T, Hayashi M, Ishikawa H, Otsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Miyabayashi T, Miura S, Tanaka H, Abe T, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Kikuchi T. Watanabe S, et al. Among authors: hayashi m. Cancer Med. 2020 May;9(9):3070-3077. doi: 10.1002/cam4.2974. Epub 2020 Mar 9. Cancer Med. 2020. PMID: 32150668 Free PMC article.
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Arita M, Watanabe S, Aoki N, Kuwahara S, Suzuki R, Goto S, Abe Y, Takahashi M, Sato M, Hokari S, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Hayashi M, Ohshima Y, Kabasawa H, Hosojima M, Koya T, Saito A, Kikuchi T. Arita M, et al. Among authors: hayashi m. Sci Rep. 2021 Jan 12;11(1):750. doi: 10.1038/s41598-020-80853-6. Sci Rep. 2021. PMID: 33437029 Free PMC article.
Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T. Sato Y, et al. Among authors: hayashi m. Transl Lung Cancer Res. 2021 Jul;10(7):3132-3143. doi: 10.21037/tlcr-21-198. Transl Lung Cancer Res. 2021. PMID: 34430353 Free PMC article.
The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events.
Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Fujisaki T, et al. Among authors: hayashi m. Front Oncol. 2021 Sep 24;11:704475. doi: 10.3389/fonc.2021.704475. eCollection 2021. Front Oncol. 2021. PMID: 34631533 Free PMC article.
7,097 results